Illinois 2023-2024 Regular Session

Illinois Senate Bill SR0028

Introduced
1/31/23  
Refer
1/31/23  
Refer
2/14/23  

Caption

NALOXONE-OPIOID OVERDOSES

Impact

The bill emphasizes the need for better access to a new 8 milligram naloxone nasal spray, which is less expensive per milligram compared to the 4 milligram version. This potential shift to a higher dosage product could significantly influence the state’s public health initiatives aimed at combating the opioid crisis. By urging an expansion of naloxone resources, the resolution places emphasis on innovative public health strategies that may change how overdose cases are managed across the state, thus aiming to ultimately reduce the number of lives lost due to opioid overdoses.

Summary

SR0028 is a Senate Resolution urging the Illinois Department of Human Services to expand its naloxone toolkit to include all FDA-approved forms of naloxone to address the state's growing opioid crisis. The resolution highlights the alarming statistics surrounding opioid overdoses in Illinois, reporting a rise to 3,013 fatalities in 2021, a significant increase compared to previous years. It indicates that the 4 milligram naloxone nasal spray, commonly used by first responders and bystanders, may not be sufficient for reversing many overdose cases, given that users often require multiple doses to revive an individual effectively.

Conclusion

In conclusion, SR0028 serves as a critical call to action for the Illinois government to reassess and improve its opioid overdose response mechanisms, particularly in the availability of naloxone products. The focus on enhancing public health resources emphasizes the urgency in curbing the rising trend of opioid-related fatalities and reflects broader societal impacts and the necessity for comprehensive strategies in tackling substance use disorders.

Contention

While the bill primarily promotes public health and safety, there's room for debate regarding the adequacy of existing overdose treatment options and whether adding more alternatives to naloxone would be more effective in tackling the opioid epidemic. Opponents of any proposed policies may raise concerns about the potential for misuse or over-reliance on naloxone as a safety net, rather than addressing the root causes of addiction. Overall, SR0028 prompts consideration of the state's opioid treatment resources and their alignment with the ongoing crisis.

Companion Bills

No companion bills found.

Previously Filed As

IL HB222

County Boards of Education - Opioid Overdose-Reversing Medications - Policy Requirements (Naloxone Access Act)

IL HB0222

County Boards of Education - Opioid Overdose-Reversing Medications - Policy Requirements (Naloxone Access Act)

IL LD710

An Act to Expand Access and Reduce Barriers to Access to Naloxone Hydrochloride and Other Opioid Overdose-reversing Medications

IL SB0401

Health: pharmaceuticals; co-prescribing of naloxone with opioid drugs; require. Amends sec. 17744b of 1978 PA 368 (MCL 333.17744b).

IL LB195

Provide immunity for administration of naloxone, nalmefene, or other federally approved opioid overdose reversal medications

IL S3324

Requires institutions of higher education to maintain supply and develop policy governing use of naloxone hydrochloride nasal spray for opioid overdose emergencies.

IL A1693

Requires institutions of higher education to maintain supply and develop policy governing use of naloxone hydrochloride nasal spray for opioid overdose emergencies.

IL SB2420

EMS-OPIOID OVERDOSE REPORTS

IL HB3645

EMS-OPIOID OVERDOSE REPORTS

IL A3800

Requires institutions of higher education to maintain supply of naloxone hydrochloride nasal spray for opioid overdose emergencies and permits emergency administration of naloxone hydrochloride nasal spray by licensed campus medical professionals and resident assistants.

Similar Bills

MO HB1625

Modifies the offenses of trafficking of drugs in the first and second degree

MO HB49

Modifies the offenses of trafficking of drugs in the first and second degree

IL HB0077

CONTROLLED SUB-XYLAZINE

CA AB1152

Controlled substances: human chorionic gonadotropin.

NJ S2036

Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances.

NJ A864

Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances.

MN HF1615

Cannabis policy bill.

MN SF2370

Omnibus Cannabis Policy Bill